South Korea-based Hanmi Pharmaceutical has reported positive outcomes from a Phase I/II clinical trial of Tivumecirnon ...

Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...

South Korea’s Celltrion has started work on a biosimilar version of pembrolizumab, Merck & Co’s blockbuster immunotherapy Keytruda ... to be known under the brand name of Ontruzant and ...

Studied in combination with Opdivo, Cabometyx saw RCC patients surviving 11 months longer than Sunitinib patients.

He declared “We’re going to be ending global freeloading” in reference to the fact that profit margins of brand name drugs ... immuno-oncology drug Keytruda (pembrolizumab) which was ...

We live in an era when many sectors are dynamic, and one of the many that’s quite active in the past several years is the ...

The combination of Padcev and Keytruda showed promising clinical activity in UTUC patients, with a 25% ORR in primary lesions and 35% in target lesions. The study included 22 patients with intact ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...